South San Francisco, United States
Cellares, founded in 2019 and headquartered in the United States, is at the forefront of revolutionizing cell therapy manufacturing. As the first Integrated Development and Manufacturing Organization (IDMO), Cellares delivers on its promise of "Accelerating Access to Life-Saving Cell Therapies" by deploying its Industry 4.0 approach to mass manufacture living drugs.
Cellares boasts fully automated solutions such as the Cell Shuttle and Cell Q, ensuring unmatched manufacturing efficiency and quality control. With the Cell Shuttle receiving the FDA's Advanced Manufacturing Technology designation for its automation success, the company stands out in the biotechnology and pharmaceutical sectors. Key clinical milestones reinforce this distinction, demonstrating real-world impact across various therapeutic domains.
Backed by a $257.00M Series D investment, with investors like DFJ Growth, Eclipse Ventures, and BlackRock, Cellares is well-positioned to expand its global network of IDMO Smart Factories located in New Jersey, the Netherlands, and Japan, poised to meet global patient demand.
